BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Holdings in argenex SE $ARGX

Key Points

• BNP PARIBAS ASSET MANAGEMENT Holding S.A. significantly increased its stake in argenex SE by 6,665.3% in Q1, owning 25,370 shares valued at approximately $15.01 million.
• Institutional investors and hedge funds collectively own over 60% of argenex's stock, highlighting strong institutional interest.
• The stock recently traded at $653.83 with a market cap of $40.01 billion, receiving multiple analyst upgrades, raising its price targets notably.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 6,665.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,370 shares of the company's stock after acquiring an additional 24,995 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.'s holdings in argenex were worth $15,014,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ARGX. Geode Capital Management LLC raised its position in shares of argenex by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 27,207 shares of the company's stock valued at $16,732,000 after acquiring an additional 458 shares in the last quarter. Mariner LLC lifted its position in shares of argenex by 15.9% in the 4th quarter. Mariner LLC now owns 3,711 shares of the company's stock worth $2,283,000 after buying an additional 509 shares during the last quarter. United Capital Financial Advisors LLC acquired a new position in shares of argenex in the 4th quarter valued at about $272,000. CANADA LIFE ASSURANCE Co grew its position in shares of argenex by 23.2% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 14,644 shares of the company's stock valued at $8,997,000 after buying an additional 2,759 shares during the last quarter. Finally, GeoWealth Management LLC raised its stake in argenex by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after acquiring an additional 18 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.

argenex Stock Up 0.2%

ARGX stock opened at $653.83 on Monday. The company has a market cap of $40.01 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 0.75 and a beta of 0.39. argenex SE has a 12-month low of $510.05 and a 12-month high of $696.21. The company has a 50 day moving average of $587.10 and a two-hundred day moving average of $597.10.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The business had revenue of $866.79 million during the quarter, compared to the consensus estimate of $776.82 million. On average, research analysts anticipate that argenex SE will post 3.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ARGX shares. Robert W. Baird upgraded argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price target on the stock in a research report on Tuesday, May 13th. Wedbush reissued an "outperform" rating and set a $715.00 price target on shares of argenex in a report on Monday, July 21st. Oppenheimer lifted their price objective on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a "hold" rating to a "buy" rating in a research report on Tuesday, July 8th. Finally, Morgan Stanley raised their price target on shares of argenex from $700.00 to $766.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Eighteen research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $746.81.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.